SUNPHARMA Sun Pharmaceutical Industries Q3 FY26 results (Oct–Dec 2025) and concall
Sun Pharmaceutical Industries Limited reported a strong Q3 FY26, driven by robust sales growth across its India and Global Innovative Medicines segments. The company achieved significant improvements in gross and EBITDA margins, alongside a healthy increase in net profit. Strategic launches like Unloxcyt in the US and Ilumya in India, coupled with plans for generic Semaglutide in India, underscore its focus on expanding its innovative and specialty portfolio, despite some softness in the US generics business.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 13.5%, net profit up 16.1% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 13,291 | 13,675 | 12,959 | 13,851 | 14,478 +9% | 15,521 +13% |
| EBITDA | 3,939 | 4,009 | 3,716 | 4,302 | 4,527 +15% | 4,948 +23% |
| Net profit | 3,037 | 2,913 | 2,154 | 2,293 | 3,125 +3% | 3,381 +16% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
